View Filing Data

Print Document View Excel Document

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Mar. 31, 2019	Apr. 29, 2019
Document and Entity Information [Abstract]
Entity Registrant Name	SHARPS COMPLIANCE CORP
Entity Central Index Key	0000898770
Current Fiscal Year End Date	--06-30
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Common Stock, Shares Outstanding		16,142,513
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
CURRENT ASSETS
Cash	$ 5,177	$ 5,155
Accounts receivable, net of allowance for doubtful accounts of $124 and $102, respectively	6,692	6,370
Inventory	3,604	3,986
Contract asset	236	0
Prepaid and other current assets	839	739
TOTAL CURRENT ASSETS	16,548	16,250
PROPERTY, PLANT AND EQUIPMENT, net	6,207	6,572
INVENTORY, net of current portion	1,079	0
OTHER ASSETS	144	149
GOODWILL	6,735	6,735
INTANGIBLE ASSETS, net	3,322	3,525
TOTAL ASSETS	34,035	33,231
CURRENT LIABILITIES
Accounts payable	2,190	1,500
Accrued liabilities	1,825	2,061
Current maturities of long-term debt	517	537
Contract liability	2,110	1,894
TOTAL CURRENT LIABILITIES	6,642	5,992
CONTRACT LIABILITY, net of current portion	387	470
OTHER LIABILITIES	191	130
DEFERRED TAX LIABILITY	199	0
LONG-TERM DEBT, net of current portion	1,077	1,465
TOTAL LIABILITIES	8,496	8,057
COMMITMENTS AND CONTINGENCIES
STOCKHOLDERS' EQUITY
Common stock, $0.01 par value per share; 40,000,000 and 20,000,000 shares authorized, respectively; 16,438,128 and 16,377,636 shares issued, respectively and 16,142,513 and 16,082,021 shares outstanding, respectively	165	164
Treasury stock, at cost, 295,615 shares repurchased	(1,554)	(1,554)
Additional paid-in capital	28,923	28,621
Accumulated deficit	(1,995)	(2,057)
TOTAL STOCKHOLDERS' EQUITY	25,539	25,174
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 34,035	$ 33,231

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) - USD ($) $ in Thousands	Mar. 31, 2019	Jun. 30, 2018
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 124	$ 102
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	40,000,000	20,000,000
Common stock, shares issued (in shares)	16,438,128	16,377,636
Common stock, shares outstanding (in shares)	16,142,513	16,082,021
Treasury stock, shares repurchased (in shares)	295,615	295,615

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
REVENUES	$ 9,451	$ 9,427	$ 32,138	$ 30,229
Cost of revenues	7,416	7,131	22,760	21,774
GROSS PROFIT	2,035	2,296	9,378	8,455
Selling, general and administrative	2,901	2,800	8,886	8,346
Depreciation and amortization	207	203	613	608
OPERATING LOSS	(1,073)	(707)	(121)	(499)
OTHER INCOME (EXPENSE)
Interest income	5	5	18	15
Interest expense	(22)	(23)	(68)	(70)
TOTAL OTHER EXPENSE	(17)	(18)	(50)	(55)
LOSS BEFORE INCOME TAXES	(1,090)	(725)	(171)	(554)
INCOME TAX EXPENSE (BENEFIT)
Current	7	(5)	(102)	9
Deferred	28	37	207	(37)
TOTAL INCOME TAX EXPENSE	35	32	105	(28)
NET LOSS	$ (1,125)	$ (757)	$ (276)	$ (526)
NET LOSS PER COMMON SHARE - Basic and Diluted (in dollars per share)	$ (0.07)	$ (0.05)	$ (0.02)	$ (0.03)
WEIGHTED AVERAGE SHARES USED IN COMPUTING NET LOSS PER COMMON SHARE:
Basic and diluted (in shares)	16,138	16,082	16,107	16,046

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit
Balance at beginning (in shares) at Jun. 30, 2017		16,304,027	295,615
Balances at beginning at Jun. 30, 2017	$ 25,287	$ 163	$ (1,554)	$ 28,063	$ (1,385)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	375			375
Issuance of restricted stock (in shares)		52,992
Issuance of restricted stock	0	$ 1		(1)
Net loss	(526)				(526)
Issuance of common shares for lease (in shares)		20,617
Issuance of common shares for lease	83			83
Balance at end (in shares) at Mar. 31, 2018		16,377,636	295,615
Balances at end at Mar. 31, 2018	25,219	$ 164	$ (1,554)	28,520	(1,911)
Balance at beginning (in shares) at Jun. 30, 2017		16,304,027	295,615
Balances at beginning at Jun. 30, 2017	$ 25,287	$ 163	$ (1,554)	28,063	(1,385)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common shares for lease (in shares)	20,617
Balance at end (in shares) at Jun. 30, 2018		16,377,636	295,615
Balances at end at Jun. 30, 2018	$ 25,174	$ 164	$ (1,554)	28,621	(2,057)
Balance at beginning (in shares) at Dec. 31, 2017		16,377,636	295,615
Balances at beginning at Dec. 31, 2017	25,862	$ 164	$ (1,554)	28,406	(1,154)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	114			114
Net loss	(757)				(757)
Balance at end (in shares) at Mar. 31, 2018		16,377,636	295,615
Balances at end at Mar. 31, 2018	25,219	$ 164	$ (1,554)	28,520	(1,911)
Balance at beginning (in shares) at Jun. 30, 2018		16,377,636	295,615
Balances at beginning at Jun. 30, 2018	25,174	$ 164	$ (1,554)	28,621	(2,057)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	303			303
Issuance of restricted stock (in shares)		60,492
Issuance of restricted stock	0	$ 1
Net loss	(276)				(276)
Balance at end (in shares) at Mar. 31, 2019		16,438,128	295,615
Balances at end at Mar. 31, 2019	25,539	$ 165	$ (1,554)	28,923	(1,995)
Balance at beginning (in shares) at Dec. 31, 2018		16,430,628	295,615
Balances at beginning at Dec. 31, 2018	26,552	$ 165	$ (1,554)	28,811	(870)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	112			112
Issuance of restricted stock (in shares)		7,500
Issuance of restricted stock	0
Net loss	(1,125)				(1,125)
Balance at end (in shares) at Mar. 31, 2019		16,438,128	295,615
Balances at end at Mar. 31, 2019	$ 25,539	$ 165	$ (1,554)	$ 28,923	$ (1,995)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (276)	$ (526)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	1,233	1,174
Bad debt expense	42	37
Non-cash lease expense	36	0
Loss (gain) on disposal of property, plant and equipment	18	(2)
Stock-based compensation expense	303	375
Deferred tax expense (benefit)	207	(37)
Changes in operating assets and liabilities:
Accounts receivable	(364)	1,413
Inventory	(461)	101
Prepaid and other assets	(139)	16
Accounts payable and accrued liabilities	499	(111)
Contract asset and contract liability	235	(317)
NET CASH PROVIDED BY OPERATING ACTIVITIES	1,333	2,123
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment	(649)	(800)
Cash proceeds from sale of property, plant and equipment	0	10
Additions to intangible assets	(254)	(58)
NET CASH USED IN INVESTING ACTIVITIES	(903)	(848)
CASH FLOWS FROM FINANCING ACTIVITIES
Repayments of long-term debt	(408)	(451)
NET CASH USED IN FINANCING ACTIVITIES	(408)	(451)
NET INCREASE IN CASH	22	824
CASH, beginning of period	5,155	4,675
CASH, end of period	5,177	5,499
SUPPLEMENTAL CASH FLOW DISCLOSURES:
Income taxes paid	31	3
Interest paid on long-term debt	68	64
NON-CASH INVESTING ACTIVITIES:
Issuance of common stock for lease	0	83
Transfer of equipment to inventory	236	166
Property, plant and equipment financed through accounts payable	16	89
Transfer of inventory to long-term	$ 1,079	$ 0

ORGANIZATION AND BACKGROUND	9 Months Ended
ORGANIZATION AND BACKGROUND	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BACKGROUND	ORGANIZATION AND BACKGROUND Organization: The accompanying unaudited condensed consolidated financial statements include the financial transactions and accounts of Sharps Compliance Corp. and its wholly owned subsidiaries, Sharps Compliance, Inc. of Texas (dba Sharps Compliance, Inc.), Sharps e-Tools.com Inc. (“Sharps e-Tools”), Sharps Manufacturing, Inc., Sharps Environmental Services, Inc. (dba Sharps Environmental Services of Texas, Inc.), Sharps Safety, Inc., Alpha Bio/Med Services LLC, Bio-Team Mobile LLC and Citiwaste, LLC (collectively, “Sharps” or the “Company”). All significant intercompany accounts and transactions have been eliminated upon consolidation. Business: Sharps is a leading full-service national provider of comprehensive waste management services including medical, pharmaceutical and hazardous for small and medium quantity generators. The Company’s solutions include Sharps Recovery System™ (formerly Sharps Disposal by Mail System^®), TakeAway Medication Recovery System™, MedSafe^®, TakeAway Recycle System™,ComplianceTRAC^SM, SharpsTracer^®, Sharps Secure^®Needle Disposal System, Complete Needle™ Collection & Disposal System, TakeAway Environmental Return System™, Pitch-It IV™ Poles, Asset Return System and Spill Kit and Recovery System. The Company also offers its route-based pick-up services in a twenty-four (24) state region of the South, Southeast and Northeast portions of the United States.

BASIS OF PRESENTATION	9 Months Ended
BASIS OF PRESENTATION	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial information and with instructions to Form 10-Q and, accordingly, do not include all information and footnotes required under generally accepted accounting principles in the United States of America ("GAAP") for complete financial statements. Additionally, the preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts. In the opinion of management, these interim condensed consolidated financial statements contain all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the consolidated financial position of the Company as of March 31, 2019, the results of its operations for the three and nine months ended March 31, 2019 and 2018, cash flows for the nine months ended March 31, 2019 and 2018 and stockholders’ equity for the three and nine months ended March 31, 2019 and 2018. The results of operations for the three and nine months ended March 31, 2019 are not necessarily indicative of the results to be expected for the entire fiscal year ending June 30, 2019. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Annual Report on Form 10-K for the year ended June 30, 2018.

SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

Revenue Recognition: In May 2014 and as subsequently amended, guidance for revenue recognition was issued which supersedes the revenue recognition requirements previously followed by the Company. The new guidance provides for a single five-step model to be applied in determining the amount and timing of the recognition of revenue related to contracts with customers. The new standard also requires additional financial statement disclosures that will enable users to understand the nature, amount, timing and uncertainty of revenue and cash flows relating to customer contracts. Companies have an option to use either a full retrospective approach or a modified retrospective approach to implement the standard. The Company adopted the standard on July 1, 2018 using the modified retrospective approach, which involves retrospectively adopting the standard by recording a cumulative effect adjustment for all uncompleted contracts at July 1, 2018. This cumulative effect was $0.3 million which decreased accumulated deficit (and increased stockholders' equity) and increased contract assets by $0.3 million. The impact that the new accounting guidance had on its consolidated financial statements and related disclosures included the following:


•	The transportation and treatment performance obligations related to the mail back and unused medication solutions, which were historically accounted for as separate performance obligations, will be accounted for as a single performance obligation under the new revenue recognition guidance. The impact of this was not material.


•	Certain costs associated with obtaining long-term contracts with customers will be capitalized and amortized over the expected economic life of the contract in future periods. The impact of this was not material.


•	The new guidance changed the timing of revenue recognition on certain of the Company’s vendor managed inventory contracts. This constituted a material portion of the cumulative effect noted above as under the new guidance, revenue recognition is no longer limited to the amounts that may be billed to the customer at the point in time in which performance obligations are satisfied.

•

The Company made a number of practical expedient elections related to the new accounting guidance, including: (i) right to invoice practical expedient that allows revenue for route-based pickup services to be recognized in the amount to which the Company has a right to invoice over time; (ii) sales and use taxes have been excluded from the transaction price; (iii) for incremental costs to obtain a contract that would be recognized over one year or less, the Company expenses those costs as incurred; and (iv) at the implementation date, new guidance was applied only to contracts that were not completed as of the date of initial application.

The components of revenues by solution which reflect a disaggregation of revenue by contract type are as follows (dollar amounts in thousands):



	Three-Months Ended March 31,
	2019		% Total		2018⁽²⁾		% Total
REVENUES BY SOLUTION:
Mailbacks	$	4,577	48.4	%	$	4,721	50.1	%
Route-based pickup services	2,259		23.9	%	1,888		20.0	%
Unused medications	1,705		18.0	%	1,832		19.4	%
Third party treatment services	26		0.3	%	44		0.5	%
Other ⁽¹⁾	884		9.4	%	942		10.0	%
Total revenues	$	9,451	100.0	%	$	9,427	100.0	%

	Nine-Months Ended March 31,
	2019		% Total		2018⁽²⁾		% Total
REVENUES BY SOLUTION:
Mailbacks	$	18,223	56.8	%	$	16,982	56.2	%
Route-based pickup services	6,465		20.1	%	5,479		18.1	%
Unused medications	4,694		14.6	%	4,321		14.3	%
Third party treatment services	206		0.6	%	815		2.7	%
Other ⁽¹⁾	2,550		7.9	%	2,632		8.7	%
Total revenues	$	32,138	100.0	%	$	30,229	100.0	%


(1)	The Company’s other products include IV poles, accessories, containers, asset return boxes and other miscellaneous items with single performance obligations.


(2)	Certain prior year amounts have been reclassified to conform to current year presentation.

The Company recognizes revenue, net of applicable sales tax, when performance obligations are satisfied through the transfer of control of promised goods or services to the Company’s customers. Control transfers once a customer has the ability to direct the use of, and obtain substantially all of the benefits from, the promised goods or services. Outbound shipping and handling activities to customers are considered fulfillment activities with the exception of mailbacks sold as part of the vendor managed inventory ("VMI") program. Shipping and handling are considered separate performance obligations for mailbacks sold under the VMI program. For performance obligations satisfied at a point in time, which applies to all contract categories except for route-based pickup services, revenue recognition occurs when there is a transfer of control or completion of service. For performance obligations satisfied over time, which applies to the route-based pickup services contract category, revenue is recognized in the amount to which the Company has a right to invoice pursuant to the right to invoice practical expedient. Provisions for certain rebates, product returns and discounts to customers are estimated at the inception of the contract, updated as needed throughout the contract term, and accounted for as reductions in sales in the same period the related sales are recorded. Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including prices charged by competitors. Rebates are estimated based on contractual terms, historical experience, trend analysis and projected market conditions in the various markets served.

Other than the Company’s mailbacks and unused medication contract categories, the Company’s solutions have a single performance obligation. The Company's mailbacks and unused medication solutions have revenue producing components that are recognized over multiple delivery points (Sharps Recovery System and various other solutions like the MedSafe and TakeAway Medication Recovery Systems referred to as “mailbacks” or "unused medications") and can consist of up to two performance obligations, or units of measure, as follows: (1) the sale of the compliance and container system, and (2) return transportation and treatment service. For mailbacks that are part of the VMI program, there is an additional element, or unit of measure, for outbound transportation. For contracts with multiple performance obligations, an estimated stand-alone selling price is determined for all performance obligations. The consideration is then allocated to the performance obligations based on their relative stand-alone selling price. The selling price for performance obligations for transportation and treatment utilizes third party evidence. The Company estimates the selling price of the compliance and container system based on the product and services provided, including the expected cost plus a margin.

The allocated transaction price for the sale of the compliance and container system is recognized upon delivery to the customer, at which time the customer has control. The allocated transaction price for the return transportation and treatment revenue is recognized when the customer returns the compliance and container system and the container has been received at the Company’s owned or contracted facilities. The compliance and container system is mailed or delivered by an alternative logistics provider to the Company’s owned or contracted facilities at which point the destruction or conversion and proof of receipt and treatment are performed on the container. Consideration received and allocated to the transportation and treatment performance obligation is recorded as a contract liability until the services are performed. Through regression analysis of historical data, the Company has determined that a certain percentage of all compliance and container systems sold may not be returned. Accordingly, a portion of the return transportation and treatment element is recognized at the point of sale. Furthermore, the current and long-term portions of amounts historically referred to deferred revenues (shown as Contract Liability on the condensed consolidated balance sheets) are determined through regression analysis and historical trends.

The VMI program includes terms that meet the “bill and hold” criteria and as such are recognized when the order is placed, title has transferred, there are no acceptance provisions and amounts are segregated in the Company’s warehouse for the customer. During the three and nine months ended March 31, 2019, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.5 million and $1.5 million, respectively. During the three and nine months ended March 31, 2018, the Company recorded revenue from inventory builds that are held in vendor managed inventory under these service agreements of $0.5 million and $2.4 million, respectively. As of March 31, 2019 and June 30, 2018, $0.9 million and $2.1 million, respectively, of solutions sold through that date were held in vendor managed inventory pending fulfillment or shipment to patients of pharmaceutical manufacturers who offer these solutions to patients in an ongoing patient support program.

The impact of adopting the new accounting guidance on the Company's condensed consolidated balance sheet as of March 31, 2019 was as follows (in thousands):



	March 31, 2019
	As Reported			Adjustments			Balance Without Adoption
Current contract asset	$	236		$	(236	)	$	—
Prepaid and other current assets	839			(33		)	806
Total current assets	16,548			(269		)	16,279
Total assets	34,035			(269		)	33,766
Current contract liability⁽¹⁾	2,110			11			2,121
Total current liabilities	6,642			11			6,653
Contract liability, net of current portion⁽¹⁾	387			—			387
Total liabilities	8,496			11			8,507
Accumulated deficit	(1,995		)	(280		)	(2,275		)
Total stockholders' equity	25,539			(280		)	25,259
Total liabilities and stockholders' equity	$	34,035		$	(269	)	$	33,766

(1): Prior period contract liabilities were referred to as deferred revenue.

The impact of adopting the new accounting guidance on the Company's condensed consolidated statement of operations for the three and nine months ended March 31, 2019 was as follows (in thousands):



	Three Months Ended March 31, 2019								Nine-Months Ended March 31, 2019
	As Reported			Adjustments		Balance Without Adoption			As Reported			Adjustments		Balance Without Adoption
Revenues	$	9,451		$	105	$	9,556		$	32,138		$	209	$	32,347
Cost of revenues	7,416			54		7,470			22,760			118		22,878
Gross profits	2,035			51		2,086			9,378			91		9,469
Selling, general and administrative	2,901			11		2,912			8,886			33		8,919
Operating income	(1,073		)	40		(1,033		)	(121		)	58		(63		)
Net loss	$	(1,125	)	$	40	$	(1,085	)	$	(276	)	$	58	$	(218	)

The estimated timing of recognition of amounts included at March 31, 2019 are as follows: for the twelve months ending March 31, 2020 - contract asset of $0.2 million and contract liability of $2.1 million and for the twelve months ending March 31, 2021 - contract liability of $0.4 million. The contract asset is related to VMI service agreements within the mailbacks contract type category when the revenue recognition exceeds the amount of consideration the Company was entitled to at the point in time of satisfying the performance obligation associated with the sale of the compliance and container system. The contract liability is related to the mailbacks and unused medications contract type categories in which cash consideration exceeds the transaction price allocated to completed performance obligations. Incremental costs to obtain contracts that are deemed to be recoverable under the new accounting guidance, primarily related to the payment of sales incentives for contracts in the route-based pickup service category, are capitalized as contract costs and included in prepaids and other current assets in the amount of $14 thousand and $39 thousand for the three and nine months ended March 31, 2019. The amortization of capitalized sales incentives, which is included in selling, general and administrative expense, totaled $3 thousand and $6 thousand for the three and nine months ended March 31, 2019.

Income Taxes: Deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when it is more likely than not that some portion or all of the deferred tax assets will not be realized. The establishment of a valuation allowance requires significant judgment and is impacted by various estimates. Both positive and negative evidence, as well as the objectivity and verifiability of that evidence, is considered in determining the appropriateness of recording a valuation allowance on deferred tax assets. A valuation allowance has been recorded to reduce the Company’s deferred tax assets to an amount that is more likely than not to be realized and is based upon the uncertainty of the realization of certain federal and state deferred tax assets related to net operating loss carryforwards and other tax attributes. The Company's deferred tax liability of $0.2 million includes $0.3 million of the accumulated tax expense related to the effect of indefinite lived assets, such as goodwill, which cannot be used as a source of future taxable income in evaluating the need for a valuation against deferred tax assets net of $0.1 million deferred tax asset for recoverable alternative minimum tax credits pursuant to the 2017 tax reform for which no valuation allowance is required. Prepaid and other current assets include realizable income taxes receivable associated with refundable alternative minimum tax credits of $0.1 million.

Accounts Receivable: Accounts receivable consist primarily of amounts due to the Company from normal business activities. Accounts receivable balances are determined to be delinquent when the amount is past due based on the contractual terms with the customer. The Company maintains an allowance for doubtful accounts to reflect the likelihood of not collecting certain accounts receivable based on past collection history and specific risks identified among uncollected accounts. Accounts receivable are charged to the allowance for doubtful accounts when the Company determines that the receivable will not be collected and/or when the account has been referred to a third party collection agency. The Company has a history of minimal uncollectible accounts.

Goodwill and Other Identifiable Intangible Assets: Finite-lived intangible assets are amortized over their respective estimated useful lives and evaluated for impairment periodically whenever events or changes in circumstances indicate that their related carrying values may not be fully recoverable. Goodwill is assessed for impairment at least annually. The Company generally performs its annual goodwill impairment analysis using a quantitative approach. The quantitative goodwill impairment test identifies the existence of potential impairment by comparing the fair value of our single reporting unit with its carrying value, including goodwill. If the fair value of a reporting unit exceeds its carrying value, the reporting unit's goodwill is considered not to be impaired. If the carrying value of a reporting unit exceeds its fair value, an impairment charge is recognized in an amount equal to that excess. The impairment charge recognized is limited to the amount of goodwill present in our single reporting unit. These estimates and assumptions could have a significant impact on whether or not an impairment charge is recognized and the amount of any such charge. The Company performs its annual impairment assessment of goodwill during the fourth quarter of each fiscal year. The Company determined that there was no impairment during the prior year ended June 30, 2018 and there have been no triggering events since that date that would warrant further impairment testing.

Stock-Based Compensation: Stock-based compensation cost for options and restricted stock awarded to employees and directors is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant).

Fair Value of Financial Instruments: The Company considers the fair value of all financial instruments, including cash, accounts receivable and accounts payable to approximate their carrying values at March 31, 2019 and June 30, 2018 due to their short-term nature. The carrying value of the Company’s debt approximates fair value due to the market rates of interest.

Reclassification of Prior Year Presentation in the Consolidated Statements of Cash Flows: Certain prior year amounts have been reclassified for consistency with the current year presentation in the Consolidated Statements of Cash Flows. The change in classification does not affect previously reported cash flows from operating activities, investing activities or financing activities in the Consolidated Statements of Cash Flows.

RECENTLY ISSUED ACCOUNTING STANDARDS	9 Months Ended
RECENTLY ISSUED ACCOUNTING STANDARDS	Mar. 31, 2019
Accounting Policies [Abstract]
RECENTLY ISSUED ACCOUNTING STANDARDS	RECENTLY ISSUED ACCOUNTING STANDARDS In February 2016, guidance for leases was issued, which requires balance sheet recognition for rights and obligations of all leases with terms in excess of twelve months. The new guidance also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. The provisions of the new guidance are effective for annual periods beginning after December 15, 2018 (effective July 1, 2019 for the Company), including interim periods within the reporting period, and early application is permitted. The Company is in the process of completing its evaluation of the impact of the new guidance on its consolidated financial statements and related disclosures. The new guidance can be applied using a modified retrospective approach at the beginning of the earliest period presented, or at the beginning of the period in which it is adopted. The Company expects to adopt the standard using the modified retrospective approach, which involves retrospectively adopting the standard by recording a cumulative effect adjustment, as of July 1, 2019. The Company expects to apply the package of practical expedients to not reassess prior conclusions related to (i) contracts containing leases, (ii) lease classification and (iii) initial direct costs. The Company also expects to make the accounting policy election for short-term leases, or leases with terms of twelve months or less, therefore the lease payments will be recorded as an expense on a straight line basis over the lease term. The Company has engaged a third-party service provider to assist in its implementation of the new lease standard, including implementation of the software package offered by the service provider to manage and account for leases under the new guidance. The Company will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company and its implementation of the new lease standard.

INCOME TAXES	9 Months Ended
INCOME TAXES	Mar. 31, 2019
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The Company’s effective tax rate for the three and nine months ended March 31, 2019 was (3.2)% and (61.4)%, respectively, reflecting primarily deferred tax expense related to the effect of indefinite lived assets, such as goodwill, which cannot be used as a source of future taxable income in evaluating the need for a valuation allowance against deferred tax assets as well as estimated state income tax. For the three and nine months ended March 31, 2019, the Company recorded total income tax expense of $35 thousand and $105 thousand, respectively. Total income tax expense for the three and nine months ended March 31, 2019 consisted of estimated federal income tax expense of $29 thousand and $85 thousand, respectively and estimated state income tax expense of $6 thousand and $20 thousand, respectively. For the three and nine months ended March 31, 2018, the Company recorded a total income tax expense (benefit) of $32 thousand and $(28) thousand, respectively, consisting of a federal tax expense (benefit) of $36 thousand and $(38) thousand, and estimated state income tax expense (benefit) of $(4) thousand and $10 thousand, respectively. The Tax Cuts and Jobs Act of 2017, enacted on December 22, 2017, contains significant changes to U.S. Tax law, including lowering the U.S. corporate tax rate to 21% and repeal of the corporate alternative minimum tax for tax years beginning on or after January 1, 2018. Other provisions in the 2017 tax reform such as interest deductibility, changes to executive compensation plans, full expensing provisions for business assets, other new minimum taxes and international taxation modifications are not expected to have material implications to the Company's financial statements.

NOTES PAYABLE AND LONG-TERM DEBT

9 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

NOTES PAYABLE AND LONG-TERM DEBT

On March 29, 2017, the Company entered into a credit agreement with a commercial bank which was subsequently amended on June 29, 2018 to extend the maturity date by two years (“Credit Agreement”). The Credit Agreement, which replaced the Company’s prior credit agreement, provides for a $14.0 million credit facility, the proceeds of which may be utilized as follows: (i) $6.0 million for working capital, letters of credit (up to $2.0 million) and general corporate purposes and (ii) $8.0 million for acquisitions. Indebtedness under the Credit Agreement is secured by substantially all of the Company’s assets with advances outstanding under the working capital portion of the credit facility at any time limited to a Borrowing Base (as defined in the Credit Agreement) equal to 80% of eligible accounts receivable plus the lesser of (i) 50% of eligible inventory and (ii) $3.0 million. Advances under the acquisition portion of the credit facility are limited to 75% of the purchase price of an acquired company and convert to a five-year term note at the time of the borrowing. Borrowings bear interest at the greater of (a) zero percent or (b) the One Month ICE LIBOR plus a LIBOR Margin of 2.5%. The LIBOR Margin may increase to as high as 3.0% depending on the Company’s cash flow leverage ratio. The interest rate as of March 31, 2019 was approximately 4.98%. The Company pays a fee of 0.25% per annum on the unused amount of the credit facility.

At March 31, 2019, long-term debt consisted of the following (in thousands):



Term loan, bearing interest at 4.98%, monthly payments of $43; maturing March 2022.	$	1,594
Less: current portion	517
Long-term debt, net of current portion	$	1,077

The Company has availability under the Credit Agreement of $12.3 million ($5.9 million for the working capital and $6.4 million for the acquisitions) as of March 31, 2019. The Company also has $0.1 million in letters of credit outstanding as of March 31, 2019.

The Credit Agreement contains affirmative and negative covenants that, among other things, require the Company to maintain a maximum cash flow leverage ratio of no more than 3.0 to 1.0 and a minimum debt service coverage ratio of not less than 1.15 to 1.00. The Credit Agreement, which expires on March 29, 2021 for the working capital portion of the Credit Agreement, also contains customary events of default which, if uncured, may terminate the Credit Agreement and require immediate repayment of all indebtedness to the lenders. The leverage ratio covenant may limit the amount available under the Credit Agreement.

Payments due on long-term debt subsequent to March 31, 2019 are as follows (in thousands):



Twelve Months Ending March 31,
2020	$	517
2021	517
2022	517
2023	43
	$	1,594

The Company utilizes performance bonds to support operations based on certain state requirements. At March 31, 2019, the Company had performance bonds outstanding covering financial assurance up to $1.0 million.

STOCK-BASED COMPENSATION

9 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

STOCK-BASED COMPENSATION

Stock-based compensation cost for options and restricted stock awarded to employees and directors is measured at the grant date, based on the calculated fair value of the award and is recognized as an expense over the requisite service period (generally the vesting period of the equity grant) net of applicable unvested shares forfeited. During the three and nine months ended March 31, 2019 and 2018, stock-based compensation amounts are as follows (in thousands):



	Three-Months Ended March 31,				Nine-Months Ended March 31,
	2019		2018		2019		2018
Stock-based compensation expense included in:
Cost of revenues	$	4	$	6	$	6	$	33
Selling, general and administrative	108		108		297		342
Total	$	112	$	114	$	303	$	375

EARNINGS PER SHARE

9 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

EARNINGS PER SHARE

Basic earnings per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed by dividing net income (loss) by the weighted average number of common shares after considering the additional dilution related to common stock options and restricted stock. In computing diluted earnings per share, the outstanding common stock options are considered dilutive using the treasury stock method.

The Company’s restricted stock awards are treated as outstanding for earnings per share calculations since these shares have full voting rights and are entitled to participate in dividends declared on common shares, if any, and undistributed earnings. As participating securities, the shares of restricted stock are included in the calculation of basic EPS using the two-class method. For the periods presented, the amount of earnings allocated to the participating securities was not material.

The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):



	Three-Months Ended March 31,						Nine-Months Ended March 31,
	2019			2018			2019			2018
Net loss, as reported	$	(1,125	)	$	(757	)	$	(276	)	$	(526	)

Weighted average common shares outstanding	16,138			16,082			16,107			16,046
Effect of dilutive stock options	—			—			—			—
Weighted average diluted common shares outstanding	16,138			16,082			16,107			16,046

Net loss per common share
Basic and diluted	$	(0.07	)	$	(0.05	)	$	(0.02	)	$	(0.03	)

Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive	1,174			401			1,176			401

EQUITY TRANSACTIONS	9 Months Ended
EQUITY TRANSACTIONS	Mar. 31, 2019
Stockholders' Equity Note [Abstract]
EQUITY TRANSACTIONS	EQUITY TRANSACTIONS During the three and nine months ended March 31, 2019 and 2018, there were no exercises of stock options to purchase shares of the Company's common stock. As of March 31, 2019, there was $0.7 million of stock compensation expense related to non-vested awards which is expected to be recognized over a weighted average period of 3.5 years. During the twelve months ended June 30, 2018, the Company issued 20,617 shares of common stock as a portion of consideration for a third-party lease agreement. The shares were issued at $4.00 per share based on the closing price on the date of grant. This issuance was exempt from registration pursuant to Section 4(a)(2) of the Securities Act. Non-cash expense recorded during the nine months ended March 31, 2019 was $36 thousand. The remaining cost will be amortized over the life of the lease and is included in Prepaid and Other Current Assets or Other Assets on the balance sheet. On November 15, 2018, the Company's stockholders approved an amendment to the Company's certificate of incorporation to increase the authorized shares of common stock from 20,000,000 to 40,000,000 shares.

GOODWILL AND INTANGIBLE ASSETS

9 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

GOODWILL AND INTANGIBLE ASSETS

At March 31, 2019 and June 30, 2018, intangible assets consisted of the following (in thousands):



		March 31, 2019							June 30, 2018
	Estimated Useful Lives	Original Amount		Accumulated Amortization			Net Amount		Original Amount		Accumulated Amortization			Net Amount
Customer relationships	7 years	$	3,007	$	(1,241	)	$	1,766	$	3,007	$	(919	)	$	2,088
Permits	6 - 15 years	1,672		(465		)	1,207		1,459		(390		)	1,069
Patents	5 - 17 years	424		(292		)	132		383		(278		)	105
Trade name	7 years	270		(106		)	164		270		(77		)	193
Non-compete	5 years	117		(64		)	53		117		(47		)	70
Total intangible assets, net		$	5,490	$	(2,168	)	$	3,322	$	5,236	$	(1,711	)	$	3,525

During both the nine months ended March 31, 2019 and 2018, amortization expense was $0.5 million. There have been no changes in the carrying amount of goodwill since June 30, 2018.

As of March 31, 2019, future amortization of intangible assets is as follows (in thousands):



Twelve Months Ending March 31,
2019	$	612
2020	611
2021	591
2022	546
2023	212
Thereafter	750
	$	3,322

INVENTORY

9 Months Ended

Mar. 31, 2019

Inventory Disclosure [Abstract]

INVENTORY

The components of inventory are as follows (in thousands):



	March 31, 2019		June 30, 2018
Raw materials	$	1,351	$	1,323
Finished goods	3,332		2,663
Total inventory	4,683		3,986
Less: current portion	3,604		3,986
Inventory, net of current portion	$	1,079	$	—

The current portion of inventory includes amounts which the Company expects to sell in the next twelve month period based on historical sales.

SIGNIFICANT ACCOUNTING POLICIES (Policies)

9 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Revenue Recognition


•	The transportation and treatment performance obligations related to the mail back and unused medication solutions, which were historically accounted for as separate performance obligations, will be accounted for as a single performance obligation under the new revenue recognition guidance. The impact of this was not material.


•	Certain costs associated with obtaining long-term contracts with customers will be capitalized and amortized over the expected economic life of the contract in future periods. The impact of this was not material.


•	The new guidance changed the timing of revenue recognition on certain of the Company’s vendor managed inventory contracts. This constituted a material portion of the cumulative effect noted above as under the new guidance, revenue recognition is no longer limited to the amounts that may be billed to the customer at the point in time in which performance obligations are satisfied.

•

Income Taxes

Accounts Receivable

Goodwill and Other Identifiable Intangible Assets

Stock-Based Compensation

Fair Value of Financial Instruments

Reclassifications of Prior Year Presentation in the Consolidated Statements of Cash Flows

Recently Issued Accounting Standards

In February 2016, guidance for leases was issued, which requires balance sheet recognition for rights and obligations of all leases with terms in excess of twelve months. The new guidance also requires additional disclosures about the amount, timing and uncertainty of cash flows arising from leases. The provisions of the new guidance are effective for annual periods beginning after December 15, 2018 (effective July 1, 2019 for the Company), including interim periods within the reporting period, and early application is permitted. The Company is in the process of completing its evaluation of the impact of the new guidance on its consolidated financial statements and related disclosures. The new guidance can be applied using a modified retrospective approach at the beginning of the earliest period presented, or at the beginning of the period in which it is adopted. The Company expects to adopt the standard using the modified retrospective approach, which involves retrospectively adopting the standard by recording a cumulative effect adjustment, as of July 1, 2019. The Company expects to apply the package of practical expedients to not reassess prior conclusions related to (i) contracts containing leases, (ii) lease classification and (iii) initial direct costs. The Company also expects to make the accounting policy election for short-term leases, or leases with terms of twelve months or less, therefore the lease payments will be recorded as an expense on a straight line basis over the lease term. The Company has engaged a third-party service provider to assist in its implementation of the new lease standard, including implementation of the software package offered by the service provider to manage and account for leases under the new guidance. The Company will continue to evaluate the standard as well as additional changes, modifications or interpretations which may impact the Company and its implementation of the new lease standard.

- Definition

Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.

+ References + Details

- Definition

Disclosure of accounting policy for trade and other accounts receivable, and finance, loan and lease receivables, including those classified as held for investment and held for sale. This disclosure may include (1) the basis at which such receivables are carried in the entity's statements of financial position (2) how the level of the valuation allowance for receivables is determined (3) when impairments, charge-offs or recoveries are recognized for such receivables (4) the treatment of origination fees and costs, including the amortization method for net deferred fees or costs (5) the treatment of any premiums or discounts or unearned income (6) the entity's income recognition policies for such receivables, including those that are impaired, past due or placed on nonaccrual status and (7) the treatment of foreclosures or repossessions (8) the nature and amount of any guarantees to repurchase receivables.

+ References + Details

SIGNIFICANT ACCOUNTING POLICIES (Tables)

9 Months Ended

Mar. 31, 2019

Accounting Policies [Abstract]

Summary of Revenue by Solution

The components of revenues by solution which reflect a disaggregation of revenue by contract type are as follows (dollar amounts in thousands):



	Three-Months Ended March 31,
	2019		% Total		2018⁽²⁾		% Total
REVENUES BY SOLUTION:
Mailbacks	$	4,577	48.4	%	$	4,721	50.1	%
Route-based pickup services	2,259		23.9	%	1,888		20.0	%
Unused medications	1,705		18.0	%	1,832		19.4	%
Third party treatment services	26		0.3	%	44		0.5	%
Other ⁽¹⁾	884		9.4	%	942		10.0	%
Total revenues	$	9,451	100.0	%	$	9,427	100.0	%

	Nine-Months Ended March 31,
	2019		% Total		2018⁽²⁾		% Total
REVENUES BY SOLUTION:
Mailbacks	$	18,223	56.8	%	$	16,982	56.2	%
Route-based pickup services	6,465		20.1	%	5,479		18.1	%
Unused medications	4,694		14.6	%	4,321		14.3	%
Third party treatment services	206		0.6	%	815		2.7	%
Other ⁽¹⁾	2,550		7.9	%	2,632		8.7	%
Total revenues	$	32,138	100.0	%	$	30,229	100.0	%


(1)	The Company’s other products include IV poles, accessories, containers, asset return boxes and other miscellaneous items with single performance obligations.


(2)	Certain prior year amounts have been reclassified to conform to current year presentation.

Schedule of Impact of New Accounting Guidance

The impact of adopting the new accounting guidance on the Company's condensed consolidated balance sheet as of March 31, 2019 was as follows (in thousands):



	March 31, 2019
	As Reported			Adjustments			Balance Without Adoption
Current contract asset	$	236		$	(236	)	$	—
Prepaid and other current assets	839			(33		)	806
Total current assets	16,548			(269		)	16,279
Total assets	34,035			(269		)	33,766
Current contract liability⁽¹⁾	2,110			11			2,121
Total current liabilities	6,642			11			6,653
Contract liability, net of current portion⁽¹⁾	387			—			387
Total liabilities	8,496			11			8,507
Accumulated deficit	(1,995		)	(280		)	(2,275		)
Total stockholders' equity	25,539			(280		)	25,259
Total liabilities and stockholders' equity	$	34,035		$	(269	)	$	33,766

(1): Prior period contract liabilities were referred to as deferred revenue.

The impact of adopting the new accounting guidance on the Company's condensed consolidated statement of operations for the three and nine months ended March 31, 2019 was as follows (in thousands):



	Three Months Ended March 31, 2019								Nine-Months Ended March 31, 2019
	As Reported			Adjustments		Balance Without Adoption			As Reported			Adjustments		Balance Without Adoption
Revenues	$	9,451		$	105	$	9,556		$	32,138		$	209	$	32,347
Cost of revenues	7,416			54		7,470			22,760			118		22,878
Gross profits	2,035			51		2,086			9,378			91		9,469
Selling, general and administrative	2,901			11		2,912			8,886			33		8,919
Operating income	(1,073		)	40		(1,033		)	(121		)	58		(63		)
Net loss	$	(1,125	)	$	40	$	(1,085	)	$	(276	)	$	58	$	(218	)

NOTES PAYABLE AND LONG-TERM DEBT (Tables)

9 Months Ended

Mar. 31, 2019

Debt Disclosure [Abstract]

Schedule of long-term debt

At March 31, 2019, long-term debt consisted of the following (in thousands):



Term loan, bearing interest at 4.98%, monthly payments of $43; maturing March 2022.	$	1,594
Less: current portion	517
Long-term debt, net of current portion	$	1,077

Schedule of payments due on long-term debt

Payments due on long-term debt subsequent to March 31, 2019 are as follows (in thousands):



Twelve Months Ending March 31,
2020	$	517
2021	517
2022	517
2023	43
	$	1,594

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(e),(f))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

+ Details

STOCK-BASED COMPENSATION (Tables)

9 Months Ended

Mar. 31, 2019

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Stock-Based Compensation

During the three and nine months ended March 31, 2019 and 2018, stock-based compensation amounts are as follows (in thousands):



	Three-Months Ended March 31,				Nine-Months Ended March 31,
	2019		2018		2019		2018
Stock-based compensation expense included in:
Cost of revenues	$	4	$	6	$	6	$	33
Selling, general and administrative	108		108		297		342
Total	$	112	$	114	$	303	$	375

EARNINGS PER SHARE (Tables)

9 Months Ended

Mar. 31, 2019

Earnings Per Share [Abstract]

Schedule of Earnings Per Share

The following information is necessary to calculate earnings per share for the periods presented (in thousands, except per-share data):



	Three-Months Ended March 31,						Nine-Months Ended March 31,
	2019			2018			2019			2018
Net loss, as reported	$	(1,125	)	$	(757	)	$	(276	)	$	(526	)

Weighted average common shares outstanding	16,138			16,082			16,107			16,046
Effect of dilutive stock options	—			—			—			—
Weighted average diluted common shares outstanding	16,138			16,082			16,107			16,046

Net loss per common share
Basic and diluted	$	(0.07	)	$	(0.05	)	$	(0.02	)	$	(0.03	)

Employee stock options excluded from computation of dilutive income per share amounts because their effect would be anti-dilutive	1,174			401			1,176			401

GOODWILL AND INTANGIBLE ASSETS (Tables)

9 Months Ended

Mar. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

At March 31, 2019 and June 30, 2018, intangible assets consisted of the following (in thousands):



		March 31, 2019							June 30, 2018
	Estimated Useful Lives	Original Amount		Accumulated Amortization			Net Amount		Original Amount		Accumulated Amortization			Net Amount
Customer relationships	7 years	$	3,007	$	(1,241	)	$	1,766	$	3,007	$	(919	)	$	2,088
Permits	6 - 15 years	1,672		(465		)	1,207		1,459		(390		)	1,069
Patents	5 - 17 years	424		(292		)	132		383		(278		)	105
Trade name	7 years	270		(106		)	164		270		(77		)	193
Non-compete	5 years	117		(64		)	53		117		(47		)	70
Total intangible assets, net		$	5,490	$	(2,168	)	$	3,322	$	5,236	$	(1,711	)	$	3,525

Schedule of future amortization of intangible assets

As of March 31, 2019, future amortization of intangible assets is as follows (in thousands):



Twelve Months Ending March 31,
2019	$	612
2020	611
2021	591
2022	546
2023	212
Thereafter	750
	$	3,322

INVENTORY (Tables)

9 Months Ended

Mar. 31, 2019

Inventory Disclosure [Abstract]

Schedule of Inventory

The components of inventory are as follows (in thousands):



	March 31, 2019		June 30, 2018
Raw materials	$	1,351	$	1,323
Finished goods	3,332		2,663
Total inventory	4,683		3,986
Less: current portion	3,604		3,986
Inventory, net of current portion	$	1,079	$	—

ORGANIZATION AND BACKGROUND (Details)	9 Months Ended
ORGANIZATION AND BACKGROUND (Details)	Mar. 31, 2019 state_region
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of route-based pick-up services in state region	24

SIGNIFICANT ACCOUNTING POLICIES - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018	Dec. 31, 2018	Jul. 01, 2018	Dec. 31, 2017	Jun. 30, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cumulative effect of new accounting standard							$ 338,000
Accumulated deficit	$ (1,995,000)		$ (1,995,000)		$ (2,057,000)
Stockholders' equity	25,539,000	$ 25,219,000	25,539,000	$ 25,219,000	25,174,000	$ 26,552,000		$ 25,862,000	$ 25,287,000
Revenue recorded from inventory builds	500,000	500,000	1,500,000	2,400,000
Solutions sold that were held in vendor managed inventory	900,000		900,000		2,100,000
Current contract asset	236,000		236,000		0
Current contract liabilities	2,110,000		2,110,000		1,894,000
Deferred contract liabilities	387,000		387,000		470,000
Capitalized incremental costs to obtain contracts	14,000		39,000
Amortization of capitalized sales incentives	3,000		6,000
Deferred tax liability	200,000		200,000
Deferred tax liability related to effect of indefinite lived assets	300,000		300,000
Deferred tax assets associated with alternative minimum tax credits	100,000		100,000
Goodwill impairment					0
Accumulated Deficit
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Cumulative effect of new accounting standard							338,000
Stockholders' equity	(1,995,000)	$ (1,911,000)	(1,995,000)	$ (1,911,000)	$ (2,057,000)	$ (870,000)		$ (1,154,000)	$ (1,385,000)
Adjustments \| Accounting Standards Update 2014-09
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Accumulated deficit	(280,000)		(280,000)				300,000
Stockholders' equity	(280,000)		(280,000)				300,000
Contract assets							$ 300,000
Current contract asset	(236,000)		(236,000)
Current contract liabilities	11,000		11,000
Deferred contract liabilities	$ 0		$ 0

SIGNIFICANT ACCOUNTING POLICIES - Summary of Revenue by Solution (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Disaggregation of Revenue [Line Items]
Total revenues	$ 9,451	$ 9,427	$ 32,138	$ 30,229
Revenue percentage	100.00%	100.00%	100.00%	100.00%
Mailbacks
Disaggregation of Revenue [Line Items]
Total revenues	$ 4,577	$ 4,721	$ 18,223	$ 16,982
Revenue percentage	48.40%	50.10%	56.80%	56.20%
Route-based pickup services
Disaggregation of Revenue [Line Items]
Total revenues	$ 2,259	$ 1,888	$ 6,465	$ 5,479
Revenue percentage	23.90%	20.00%	20.10%	18.10%
Unused medications
Disaggregation of Revenue [Line Items]
Total revenues	$ 1,705	$ 1,832	$ 4,694	$ 4,321
Revenue percentage	18.00%	19.40%	14.60%	14.30%
Third party treatment services
Disaggregation of Revenue [Line Items]
Total revenues	$ 26	$ 44	$ 206	$ 815
Revenue percentage	0.30%	0.50%	0.60%	2.70%
Other
Disaggregation of Revenue [Line Items]
Total revenues	$ 884	$ 942	$ 2,550	$ 2,632
Revenue percentage	9.40%	10.00%	7.90%	8.70%

SIGNIFICANT ACCOUNTING POLICIES - Summary of Impact of New Accounting Guidance (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Jul. 01, 2018	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Current contract asset	$ 236		$ 236				$ 0
Prepaid and other current assets	839		839				739
Total current assets	16,548		16,548				16,250
Total assets	34,035		34,035				33,231
Current contract liability	2,110		2,110				1,894
Total current liabilities	6,642		6,642				5,992
Contract liability, net of current portion	387		387				470
Total liabilities	8,496		8,496				8,057
Accumulated deficit	(1,995)		(1,995)				(2,057)
Total stockholders' equity	25,539	$ 25,219	25,539	$ 25,219	$ 26,552		25,174	$ 25,862	$ 25,287
Total liabilities and stockholders' equity	34,035		34,035				$ 33,231
Revenues	9,451	9,427	32,138	30,229
Cost of revenues	7,416	7,131	22,760	21,774
Gross profits	2,035	2,296	9,378	8,455
Selling, general and administrative	2,901	2,800	8,886	8,346
Operating income	(1,073)	(707)	(121)	(499)
Net loss	(1,125)	$ (757)	(276)	$ (526)
Balance Without Adoption
Revenue, Initial Application Period Cumulative Effect Transition [Line Items]
Current contract asset	0		0
Prepaid and other current assets	806		806
Total current assets	16,279		16,279
Total assets	33,766		33,766
Current contract liability	2,121		2,121
Total current liabilities	6,653		6,653
Contract liability, net of current portion	387		387					<